ABSTRACT Current seasonal influenza virus vaccines engender antibody-mediated protection that is hemagglutinin (HA) subtype specific and relatively short-lived. Coverage for other subtypes or even variants within a subtype could be improved from a better understanding of the factors that promote HA-specific antibody cross-reactivity. Current assays to evaluate cross-reactivity. such a... https://www.roneverhart.com/DAFT-PUNK-HUMAN-AFTER-ALL-2LP/